Cyanoacrylate Adhesive For Treatment of Great Saphenous Vein Incompetence without Tumescent Anaesthesia and without Compression Therapy: Preliminary Results of the European Multicenter eSCOPE Study

Thomas M. Proebstle, Jens Alm, Lars Rasmussen, Sameh Dimitri, Mark Whiteley, Alun Davies

Objectives: Short term efficacy and side effect profile of an endovenous cyanoacrylate (CA) adhesive implant, delivered with a catheter-based administration system for the treatment of incompetent great saphenous veins (GSVs).

Methods: 60 patients are expected to receive study treatment in seven European centers, Germany, Denmark and UK. Per protocol, perivenous tumescent anesthesia and compression stockings were omitted.   Duplex ultrasound and clinical follow-up was performed immediately after the procedure and at 24-72 hours, 1, 3 and 6 months. During the first months after treatment patients recorded pain and side-effects in a diary

Results: 52 patients were treated. Median follow-up was 3 months (range 48h – 6mo). Mean CA volume was 1.26 +/-0.44 ml, (range 0.63-2.25). At 48h all 52 patients (100%) demonstrated complete closure .   One recanalization was observed at 3-month, according to Kaplan-Meier analysis occlusion rate was 98% at 6 months. Phlebitis was observed in 2 cases (4%), one received NSAIDs. 1 patient (2%) showed a thread-like thrombus extension into the common femoral vein with a length of 6 mm resolving spontaneously without clinical sequelae. VCSS improved from a mean of 4.3+/-2.2 at baseline to 1.7+/-1.7 at 1 month.

Conclusions: Endovenous CA for closure of insufficient GSVs proved to be feasible, safe and effective without the use of tumescent anesthesia or the requirement of medical compression stockings.

Abstract Format

Abstracts should use the Objectives, Methods, Results and Conclusion format.

1. Objectives and/or Purpose (approximately 30 words): A precise statement of the primary objective(s) or
purpose of the study/study question; we recommend at least three objectives in a numbered format, starting
with a verb (i.e., Use, Implement, Integrate, Perform, etc.).

2. Methods (limited to 65 words): Summarize the following:
• Study Design
• Year(s)/Month(s) Study Conducted
• Disease/Condition Studied
• Subjects Studied
• Setting in Which Subjects Studied
• Intervention(s)
• Outcome Measurement(s)
• Independent Variables
• Preliminary Analyses (Analysis of Ongoing Study)

3. Results (limited to 90 words): State the main outcome(s) of the study, including confidence levels or P
values.

4. Conclusion (limited to 65 words): A precise statement of conclusion(s) directly supported by the results,
giving equal emphasis to positive and negative scientific findings.

Abstrac t Text

All abstracts must be in English. Standard abbreviations may be used without definition. Nonstandard abbreviations
(please keep to a minimum) must be placed in parentheses after the first use of the word or phrase
abbreviated. Abstracts should be no longer than 250 words in length. Abstracts longer than 250 words will
be truncated and given a lower ranking. To ensure educational quality and ease of comprehension, abstracts
selected for oral presentation must be related in conversational English. Those in need of a translator may do so
but are responsible to confirm said translator is capable of responding to live audience questions in an accurate
and timely manner. Failure to do so is not in keeping with the academic standards of presentation and may result
in sanctions by the ACP Program Committee. Your consideration and compliance with this expectation is appreciated.

Special Note: DO NOT place the author(s) or presenter(s) name(s) or any affiliations within the text of your abstract.
This will be linked to the author information via the screens you will fill in during the submission process,
and it will be printed with full author acknowledgement based on those screens. Omitting author information in
the abstract text allows for your abstract to be reviewed in a blinded fashion. Placing